<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hemoperfusion</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hemoperfusion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hemoperfusion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nikolas Harbord, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hemoperfusion is an extracorporeal blood purification modality that consists of the passage of anticoagulated whole blood through a device, usually a column, that contains adsorbent particles [<a href="#rid1">1</a>]. Sometimes referred to as hemadsorption, hemoperfusion is used for the removal of toxins in poisonings and cytokines from septic and inflamed patients [<a href="#rid2">2-5</a>]. An increasing range of pathogens and molecules can also be removed with novel devices. </p><p>However, although hemoperfusion is effective for removing toxins, it is rarely used in the treatment of poisoning [<a href="#rid6">6,7</a>] and is among the least available extracorporeal modalities for detoxification [<a href="#rid8">8</a>].</p><p>An overview of hemoperfusion, including the clinical settings in which this technology may be used, is reviewed here. A general introduction to the treatment of poisoning as well as a discussion of the use of other technologies for poisoning, such as hemodialysis and peritoneal dialysis, are presented separately. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a> and  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM</span><span class="headingEndMark"> — </span>In hemoperfusion, whole blood is passed through a column that contains fixed adsorbent particles [<a href="#rid1">1</a>]. Engineering of the porous structure of these particles produces columns with varied adsorption properties. Toxins with molecular weights ranging from 100 to 40,000 daltons bind to the particles and are removed as blood exits the column. Binding is through physical adsorption, governed by molecular size and lipophilicity, through hydrophobic interactions, van der Waals interactions, hydrogen bonding, or ionic attraction. Higher-molecular-weight solutes are adsorbed less efficiently [<a href="#rid9">9</a>].</p><p>There are two major types of adsorbent particles, including activated charcoal and resins (such as the hydrocarbon polymer, polystyrene). Charcoal has greater affinity for water-soluble molecules, while resins have greater affinity for lipid-soluble molecules. Although available in Europe, resin columns for hemoperfusion are not available in the United States, except for emergency or compassionate use. </p><p>The adsorbent may be modified to provide selective removal of endotoxin, cytokines, or antibodies. (See <a class="local">'Sepsis'</a> below and <a class="local">'Other'</a> below.)</p><p>Of note, AN69 hemofilters have a hydrophilic membrane structure (composed of acrylonitrile and sodium methallyl sulfonate copolymer) and adsorb proteins like a hemoperfusion column [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H4"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>The major accepted indication for hemoperfusion is the removal of lipid-soluble, highly protein-bound toxins (ie, poisoning) that are not easily removed with standard hemodialysis. Hemoperfusion has also been used in some centers for the removal of cytokines in septic patients, the removal of endotoxin or pathogens, the removal of antibodies and antibody-antigen complexes in autoimmune and other disorders, and the removal of hepatic toxins in liver failure.</p><p class="headingAnchor" id="H3783363807"><span class="h2">Poisoning</span><span class="headingEndMark"> — </span>Hemoperfusion is preferred to hemodialysis alone for paraquat poisoning. Hemoperfusion provides better early clearance of paraquat compared with high-flux hemodialysis [<a href="#rid11">11</a>]. Several retrospective studies have shown that hemoperfusion is associated with increased survival when performed within four to five hours of paraquat ingestion [<a href="#rid12">12-14</a>]. Hemodialysis or continuous venovenous hemofiltration (CVVH) may also be required in patients with reduced kidney function and indications for dialysis [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/337.html" rel="external">"Paraquat poisoning", section on 'Indications for extracorporeal therapies'</a> and  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.) </p><p>Other indications for hemoperfusion in poisoning are less clear. Hemoperfusion used to be preferred to hemodialysis for the removal of large and lipophilic or protein-bound toxins, including barbiturates [<a href="#rid17">17</a>], <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid18">18</a>], <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> [<a href="#rid19">19</a>], <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid20">20</a>], amanita mushrooms [<a href="#rid21">21,22</a>], and aluminum after chelation with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> [<a href="#rid23">23,24</a>]. This initial preference was based upon comparison of hemoperfusion and standard dialysis hemofilters with cuprophane membranes before they were supplanted by modern high-flux [large-pore] dialyzers [<a href="#rid25">25</a>]. A poisoning workgroup has published treatment guidelines favoring hemodialysis over hemoperfusion for poisoning due to barbiturates [<a href="#rid17">17</a>], theophylline [<a href="#rid18">18</a>], valproic acid [<a href="#rid19">19</a>], and carbamazepine [<a href="#rid20">20</a>], and thallium [<a href="#rid26">26</a>]. </p><p>Even if high-flux hemodialysis and hemoperfusion are comparable with respect to toxin removal, the increased availability, decreased cost, familiarity, and lower complication rate favors the use of hemodialysis  (<a class="graphic graphic_table graphicRef52887" href="/z/d/graphic/52887.html" rel="external">table 1</a>) [<a href="#rid27">27</a>].</p><p>Another advantage of hemodialysis over hemoperfusion is that it corrects concurrent metabolic or acid-base disturbances that may be present and can increase or lower body temperature in the severely hypothermic or hyperthermic patient [<a href="#rid1">1</a>].</p><p>In addition to paraquat, hemoperfusion may yet have an indication in poisonings. Several hours of hemoperfusion may provide additional cytokine reduction and benefit in poisoning due to wasp envenomation [<a href="#rid28">28</a>]. <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> toxicity can be treated with hemoperfusion if antidote (<a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> or carboxypeptidase G2 enzyme) is unavailable [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1804428316"><span class="h2">Sepsis</span><span class="headingEndMark"> — </span>Hemoperfusion devices containing either the antibiotic <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a> or a polystyrene divinylbenzene copolymer have been specifically developed for removing cytokines from patients with sepsis or endotoxemia. These devices have been approved for use in Europe and Japan but are not available in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">Polymyxin B</a><strong> </strong>– An adsorbent column containing resin bound to the antibiotic polymyxin B removes endotoxins that activate the inflammatory cascade [<a href="#rid30">30</a>]. Endotoxin levels decrease within minutes after starting hemoperfusion [<a href="#rid30">30</a>]. Some studies have shown improvements in hemodynamic measures (mean arterial pressure, catecholamine dose), respiratory function, and the sepsis-related organ failure (SOFA) scores [<a href="#rid31">31</a>]. However, large randomized, controlled trials and a meta-analysis have not shown a mortality benefit with this therapy [<a href="#rid31">31-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/1631.html" rel="external">"Investigational and ineffective pharmacologic therapies for sepsis", section on 'Cytokine and endotoxin inactivation or removal'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polystyrene divinylbenzene copolymer</strong> ─ Polystyrene divinylbenzene copolymer columns have been developed for use with intermittent hemodialysis, continuous kidney replacement therapy (CKRT) machine, cardiopulmonary bypass, or extracorporeal membrane oxygenation (ECMO) blood circuits [<a href="#rid36">36-38</a>]. Although data from small observational studies reported improvements in hemodynamic status/vasopressor dose, organ dysfunction, and cytokine levels (particularly interleukin [IL] 6 and IL 8) in patients with septic shock [<a href="#rid36">36,39</a>] and acute respiratory distress syndrome (ARDS) [<a href="#rid37">37</a>], a larger randomized trial of patients with sepsis did not confirm these benefits [<a href="#rid40">40,41</a>]. In a small study of patients with sepsis, compared with CVVH, combining hemoperfusion and high-volume hemofiltration led to cytokine reduction and reduction in mortality, although the relative contribution of hemoperfusion and high-volume hemofiltration to the outcomes is uncertain [<a href="#rid42">42</a>]. Thus, the use of these hemoperfusion columns in inflammatory conditions remains experimental. (See  <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">"Continuous kidney replacement therapy in acute kidney injury", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyethylene </strong>– A column containing polyethylene particles designed to filter pathogens and cytokines from the blood is currently undergoing clinical trials. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AN69 hemofilter </strong>–<strong> </strong>An interesting device that is a high-flux dialyzer and also an adsorptive surface is the AN69 hemofilter. More recently, AN69 hemofilters with heparin surface grafts and additional polyethyleneimine have been designed for the treatment of sepsis. </p><p></p><p class="headingAnchor" id="H2570371907"><span class="h2">Other</span><span class="headingEndMark"> — </span>The removal of pathogenic antibodies and antibody-antigen complexes has been used in multiple conditions including systemic lupus erythematosus, vasculitis, antiglomerular basement membrane disease, pemphigus, atopic dermatitis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis [<a href="#rid43">43-47</a>], and as a preconditioning protocol to allow for ABO-incompatible kidney transplantation [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a> and  <a class="medical medical_review" href="/z/d/html/113661.html" rel="external">"Kidney transplantation in adults: ABO-incompatible transplantation", section on 'Overview of desensitization'</a>.)</p><p>Although the standard of care is plasmapheresis/therapeutic plasma exchange (TPE), a possible advantage of hemoperfusion/immunoadsorption is more specific immune modulation without the requirement of plasma product infusions. However, immunoadsorption is considered experimental for such conditions and has not supplanted apheresis alone for removal of pathogenetic antibodies [<a href="#rid43">43-45</a>].</p><p>The removal of hepatic toxins by some extracorporeal liver assist devices also involves adsorption. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis", section on 'Artificial hepatic assist devices'</a>.)</p><p>The experimental use of resin hemoperfusion for cytokine adsorption in the setting of critical illness and cytokine release syndrome or "storm" has been employed in patients receiving CAR-T cell therapy or those with hemophagocytic lymphohistiocytosis and, more recently, patients with severe coronavirus disease 2019 (COVID-19) infection [<a href="#rid49">49,50</a>]. While reports often describe improved hemodynamics or gas exchange, clinical benefit is uncertain due to lack of controlled studies. A significant concern may be the indiscriminate reduction of cytokines, both pro- and anti-inflammatory, based on size rather than function.</p><p>Hemoperfusion with polystyrene divinylbenzene copolymer columns weekly or biweekly in patients with end-stage kidney disease on hemodialysis may improve sleep disturbance and melatonin [<a href="#rid51">51</a>].</p><p>A pilot trial to assess the benefit of polystyrene divinylbenzene copolymer column hemoperfusion during cardiopulmonary bypass did not show reduction in cytokines or improvement in clinical outcomes [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H570699794"><span class="h1">PRESCRIPTION</span><span class="headingEndMark"> — </span>Hemoperfusion is conducted using dialysis blood lines and a dialysis machine apparatus containing a blood pump and pressure gauges. The column generally contains between 100 and 300 g of activated charcoal or 300 to 650 g of resin. A list of some of the clinically available hemoperfusion devices and the contained sorbents is shown in the table  (<a class="graphic graphic_table graphicRef79263" href="/z/d/graphic/79263.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H754098861"><span class="h2">Vascular access</span><span class="headingEndMark"> — </span>We use a tunneled or nontunneled central venous hemodialysis catheter for most patients. If an arteriovenous fistula or graft is available when the poisoned patient also has end-stage kidney disease, it is appropriate to cannulate this access for hemoperfusion.</p><p class="headingAnchor" id="H740681148"><span class="h2">Selection of cartridge</span><span class="headingEndMark"> — </span>The choice of cartridge depends upon body size and drug involved. A small cartridge should be utilized for a child or a patient with a tiny habitus. The cartridge will contain polymer-coated charcoal or resin, typically polystyrene divinylbenzene copolymer (Amberlite XAD-4). </p><p class="headingAnchor" id="H249860928"><span class="h2">Anticoagulation</span><span class="headingEndMark"> — </span>Anticoagulation is typically required for hemoperfusion, either with systemic heparin or regional citrate. Heparin requirements are likely to exceed that necessary for hemodialysis due to heparin adsorption. The activated clotting time (ACT) should be maintained at approximately 2 to 2.5 times normal or an activated plasma thromboplastin time (APTT) of approximately 60 to 70 seconds. <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">Regional citrate anticoagulation</a> is used in some centers (see  <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a>). Priming and flushing of the devices are achieved with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>.</p><p class="headingAnchor" id="H2621253700"><span class="h2">Blood flow</span><span class="headingEndMark"> — </span>The minimum blood flow for efficient drug removal is approximately 300 mL/min. Blood flow should be increased as possible to approximately 450 mL/min.</p><p>Pressure gauges detect interior rises in pressure, which indicate clot formation occurring inside the device; this is rare if heparinization is controlled via adequate monitoring of the ACT.</p><p class="headingAnchor" id="H1935163846"><span class="h2">Duration</span><span class="headingEndMark"> — </span>Intermittent hemoperfusion is usually performed for approximately four hours. Longer treatment times for charcoal hemoperfusion are unlikely to provide additional clearance due to device saturation. Treatment duration of only two hours has been standard in trials for endotoxin removal with a <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a> column and some other devices. Reuse of devices is not performed.</p><p>Repeat treatments may be necessary once the drug redistributes from tissues into the plasma following its removal from the plasma compartment (ie, "rebound"). This is associated with increased signs of drug toxicity such as neurologic dysfunction or coma.</p><p>We do not use continuous hemoperfusion. Intermittent hemoperfusion is more efficient in addressing the rebound effect and reduces the hematologic side effects of prolonged hemoperfusion (see <a class="local">'Complications'</a> below). Intermittent therapies also allow the replacement of saturated devices with fresh devices, which restores maximal extraction ratio.</p><p class="headingAnchor" id="H1927840823"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Drug levels should be monitored, if available. However, reporting of drug levels often takes too long to be clinically useful. In such cases, the patient is started on hemoperfusion based on the history of known or suspected poisoning, and the clinical response is used to guide therapy. Platelet levels should be regularly monitored, such as after each treatment, as decreases in platelet count are not uncommon. (See <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The most common side effect of hemoperfusion is thrombocytopenia [<a href="#rid53">53-55</a>]. The platelet count usually returns to normal within 24 to 48 hours following hemoperfusion [<a href="#rid53">53,54</a>]. In addition to thrombocytopenia, bleeding risk may also increase due to impaired platelet aggregation and increased fibrinolysis noted during charcoal hemoperfusion [<a href="#rid56">56</a>]. Thrombocytopenia may be worse with resin than with charcoal. </p><p>Other side effects include hypocalcemia, hypoglycemia, and neutropenia [<a href="#rid54">54</a>]. These complications are usually minor and correct spontaneously or can be corrected. There is also a mild reduction of one to two degrees in body temperature.</p><p>Hypotension is infrequent but well described [<a href="#rid55">55</a>]. If needed, vasopressor agents should be administered distal to the sorbent devices to minimize their adsorption.</p><p>The frequency of side effects with charcoal columns has been reduced by coating with a polymer solution that reduces platelet adhesion and complement activation.</p><p class="headingAnchor" id="H1937475130"><span class="h1">COMBINED HEMODIALYSIS/EXTRACORPOREAL TREATMENT AND HEMOPERFUSION</span><span class="headingEndMark"> — </span>Hemoperfusion does not remove fluid or correct electrolyte imbalances such as hyperkalemia. Among patients with acute kidney injury, hemodialysis may be also be required.</p><p>Hemodialysis may be performed first, followed immediately by hemoperfusion, using the same bloodlines and apparatus.</p><p>Alternatively, hemoperfusion may be combined with other extracorporeal treatments such as continuous kidney replacement therapy (CKRT), usually continuous venovenous hemofiltration (CVVH) with the hemoperfusion column placed in the blood circuit upstream from the hemofilter [<a href="#rid30">30,36</a>]. Alternatively, hemoperfusion alone for several hours may be followed by CVVH for the majority or remainder of a day. Finally, hemoperfusion can be combined with extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass. </p><p>The indications for dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p class="headingAnchor" id="H3721067306"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H7169304"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Hemoperfusion consists of the passage of anticoagulated blood through a device containing adsorbent particles. The most commonly available adsorbent particles are activated charcoal and resin. (See <a class="local">'Introduction'</a> above and <a class="local">'Mechanism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The major accepted indication for hemoperfusion is the removal of lipid-soluble, highly protein-bound toxins (ie, poisoning) that are not easily removed with standard hemodialysis. Hemoperfusion may be superior to high-flux hemodialysis for paraquat removal. For other lipid-soluble or highly protein-bound drugs, high-flux hemodialysis appears to work as well as hemoperfusion and is generally preferred. (See <a class="local">'Poisoning'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemoperfusion has also been used in some centers for the removal of cytokines in septic patients, the removal of endotoxin or pathogens, the removal of antibodies and antibody-antigen complexes in autoimmune and other disorders, and the removal of hepatic toxins in liver failure. (See <a class="local">'Sepsis'</a> above and <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Platelet depletion is the most important side effect of hemoperfusion. Other side effects include hypocalcemia, hypoglycemia, a transient fall in white blood cell count, and a mild reduction in body temperature. Hypotension is infrequent. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="headingAnchor" id="H1801031438"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James F Winchester, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Winchester JF, Harbord NB, Charen E, Ghannoum M. Use of dialysis and hemoperfusion in treatment of poisioning. In: Handbook of Dialysis, 5th ed, Daugirdas JT, Blake PG, Ing TS (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2015. p.368.</li><li><a class="nounderline abstract_t">MUIRHEAD EE, REID AF. A resin artificial kidney. J Lab Clin Med 1948; 33:841.</a></li><li><a class="nounderline abstract_t">Hampel G, Crome P, Widdop B, Goulding R. Experience with fixed-bred charcoal haemoperfusion in the treatment of severe drug intoxication. Arch Toxicol 1980; 45:133.</a></li><li><a class="nounderline abstract_t">Gelfand MC, Winchester JF, Knepshield JH, et al. Treatment of severe drug overdosage with charcoal hemoperfusion. Trans Am Soc Artif Intern Organs 1977; 23:599.</a></li><li><a class="nounderline abstract_t">Verpooten GA, De Broe ME. Combined hemoperfusion-hemodialysis in severe poisoning: kinetics of drug extraction. Resuscitation 1984; 11:275.</a></li><li><a class="nounderline abstract_t">Shalkham AS, Kirrane BM, Hoffman RS, et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006; 48:239.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report. Clin Toxicol (Phila) 2017; 55:1072.</a></li><li><a class="nounderline abstract_t">Bouchard J, Lavergne V, Roberts DM, et al. Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey. Nephrol Dial Transplant 2017; 32:699.</a></li><li><a class="nounderline abstract_t">Denti E, Luboz MP, Tessore V. Adsorption characteristics of cellulose acetate coated charcoals. J Biomed Mater Res 1975; 9:143.</a></li><li><a class="nounderline abstract_t">Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the world's first high permeability membrane. Contrib Nephrol 2011; 173:119.</a></li><li><a class="nounderline abstract_t">Hong SY, Yang JO, Lee EY, Kim SH. Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health 2003; 19:17.</a></li><li><a class="nounderline abstract_t">Rao R, Bhat R, Pathadka S, et al. Golden Hours in Severe Paraquat Poisoning-The Role of Early Haemoperfusion Therapy. J Clin Diagn Res 2017; 11:OC06.</a></li><li><a class="nounderline abstract_t">Wang HR, Pan J, Shang AD, Lu YQ. Time-dependent haemoperfusion after acute paraquat poisoning. Sci Rep 2017; 7:2239.</a></li><li><a class="nounderline abstract_t">Li A, Li W, Hao F, Wang H. Early Stage Blood Purification for Paraquat Poisoning: A Multicenter Retrospective Study. Blood Purif 2016; 42:93.</a></li><li><a class="nounderline abstract_t">Park S, Lee S, Park S, et al. Concurrent Hemoperfusion and Hemodialysis in Patients with Acute Pesticide Intoxication. Blood Purif 2016; 42:329.</a></li><li><a class="nounderline abstract_t">Li C, Hu D, Xue W, et al. Treatment Outcome of Combined Continuous Venovenous Hemofiltration and Hemoperfusion in Acute Paraquat Poisoning: A Prospective Controlled Trial. Crit Care Med 2018; 46:100.</a></li><li><a class="nounderline abstract_t">Mactier R, Laliberté M, Mardini J, et al. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis 2014; 64:347.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Wiegand TJ, Liu KD, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:215.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Laliberté M, Nolin TD, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:454.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Yates C, Galvao TF, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2014; 52:993.</a></li><li><a class="nounderline abstract_t">Aji DY, Calişkan S, Nayir A, et al. Haemoperfusion in Amanita phalloides poisoning. J Trop Pediatr 1995; 41:371.</a></li><li><a class="nounderline abstract_t">Monhart V. [Amanita poisoning and the importance of sorption hemoperfusion in its therapy]. Vnitr Lek 1997; 43:686.</a></li><li><a class="nounderline abstract_t">Chang TM, Barre P. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Lancet 1983; 2:1051.</a></li><li><a class="nounderline abstract_t">Weiss LG, Danielson BG, Fellström B, Wikström B. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency. Nephron 1989; 51:325.</a></li><li><a class="nounderline abstract_t">Winchester JF. Dialysis and hemoperfusion in poisoning. Adv Ren Replace Ther 2002; 9:26.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Nolin TD, Goldfarb DS, et al. Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2012; 7:1682.</a></li><li><a class="nounderline abstract_t">Lavergne V, Nolin TD, Hoffman RS, et al. The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. Clin Toxicol (Phila) 2012; 50:403.</a></li><li><a class="nounderline abstract_t">Li L, Bo W, Chen H, et al. Hemoperfusion plus continuous veno-venous hemofiltration in the treatment of patients with multiple organ failure after wasp stings. Int J Artif Organs 2020; 43:143.</a></li><li><a class="nounderline abstract_t">Rosales A, Madrid A, Muñoz M, et al. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available. Front Pediatr 2021; 9:635152.</a></li><li><a class="nounderline abstract_t">Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg 2017; 1:105.</a></li><li><a class="nounderline abstract_t">Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445.</a></li><li><a class="nounderline abstract_t">Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41:975.</a></li><li><a class="nounderline abstract_t">Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA 2018; 320:1455.</a></li><li><a class="nounderline abstract_t">Fujii T, Ganeko R, Kataoka Y, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44:167.</a></li><li><a class="nounderline abstract_t">Putzu A, Schorer R, Lopez-Delgado JC, et al. Blood Purification and Mortality in Sepsis and Septic Shock: A Systematic Review and Meta-analysis of Randomized Trials. Anesthesiology 2019; 131:580.</a></li><li><a class="nounderline abstract_t">Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21:74.</a></li><li><a class="nounderline abstract_t">Träger K, Schütz C, Fischer G, et al. Cytokine Reduction in the Setting of an ARDS-Associated Inflammatory Response with Multiple Organ Failure. Case Rep Crit Care 2016; 2016:9852073.</a></li><li><a class="nounderline abstract_t">Träger K, Skrabal C, Fischer G, et al. Hemoadsorption treatment with CytoSorb® in patients with extracorporeal life support therapy: A case series. Int J Artif Organs 2020; 43:422.</a></li><li><a class="nounderline abstract_t">Hawchar F, László I, Öveges N, et al. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care 2019; 49:172.</a></li><li><a class="nounderline abstract_t">Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One 2017; 12:e0187015.</a></li><li><a class="nounderline abstract_t">Bernardi MH, Rinoesl H, Dragosits K, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care 2016; 20:96.</a></li><li><a class="nounderline abstract_t">Chu L, Li G, Yu Y, et al. Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock. Medicine (Baltimore) 2020; 99:e19058.</a></li><li><a class="nounderline abstract_t">Yamaji K. Immunoadsorption for collagen and rheumatic diseases. Transfus Apher Sci 2017; 56:666.</a></li><li><a class="nounderline abstract_t">Stummvoll G, Aringer M, Handisurya A, Derfler K. Immunoadsorption in Autoimmune Diseases Affecting the Kidney. Semin Nephrol 2017; 37:478.</a></li><li><a class="nounderline abstract_t">Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev 2016; 15:38.</a></li><li><a class="nounderline abstract_t">Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial 2012; 16:311.</a></li><li><a class="nounderline abstract_t">Oji S, Nomura K. Immunoadsorption in neurological disorders. Transfus Apher Sci 2017; 56:671.</a></li><li><a class="nounderline abstract_t">Lo P, Sharma A, Craig JC, et al. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2016; 100:933.</a></li><li><a class="nounderline abstract_t">Ramírez-Guerrero G, Torres Cifuentes V, Baghetti Hernández R, et al. Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report. Blood Purif 2021; 50:575.</a></li><li><a class="nounderline abstract_t">Song T, Hayanga J, Durham L, et al. CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry. Front Med (Lausanne) 2021; 8:773461.</a></li><li><a class="nounderline abstract_t">Gu YH, Yang XH, Pan LH, et al. Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis. Int J Artif Organs 2019; 42:347.</a></li><li><a class="nounderline abstract_t">Poli EC, Alberio L, Bauer-Doerries A, et al. Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial. Crit Care 2019; 23:108.</a></li><li><a class="nounderline abstract_t">Weston MJ, Langley PG, Rubin MH, et al. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977; 18:897.</a></li><li><a class="nounderline abstract_t">Yang X, Xin S, Zhang Y, Li T. Early hemoperfusion for emergency treatment of carbamazepine poisoning. Am J Emerg Med 2018; 36:926.</a></li><li><a class="nounderline abstract_t">Kittanamongkolchai W, El-Zoghby ZM, Eileen Hay J, et al. Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatol Int 2017; 11:384.</a></li><li><a class="nounderline abstract_t">Park S, Islam MI, Jeong JH, et al. Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication. Sci Rep 2019; 9:13325.</a></li></ol></div><div id="topicVersionRevision">Topic 1901 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Winchester JF, Harbord NB, Charen E, Ghannoum M. Use of dialysis and hemoperfusion in treatment of poisioning. In: Handbook of Dialysis, 5th ed, Daugirdas JT, Blake PG, Ing TS (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2015. p.368.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18869571" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A resin artificial kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7469790" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Experience with fixed-bred charcoal haemoperfusion in the treatment of severe drug intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/910388" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of severe drug overdosage with charcoal hemoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6326227" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Combined hemoperfusion-hemodialysis in severe poisoning: kinetics of drug extraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860189" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The availability and use of charcoal hemoperfusion in the treatment of poisoned patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185815" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339843" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1176475" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adsorption characteristics of cellulose acetate coated charcoals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865784" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : AN69: Evolution of the world's first high permeability membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15462533" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384906" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Golden Hours in Severe Paraquat Poisoning-The Role of Early Haemoperfusion Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533543" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Time-dependent haemoperfusion after acute paraquat poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27189189" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early Stage Blood Purification for Paraquat Poisoning: A Multicenter Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771705" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Concurrent Hemoperfusion and Hemodialysis in Patients with Acute Pesticide Intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29116999" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment Outcome of Combined Continuous Venovenous Hemofiltration and Hemoperfusion in Acute Paraquat Poisoning: A Prospective Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24998037" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715736" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950372" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355482" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606449" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Haemoperfusion in Amanita phalloides poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9601885" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : [Amanita poisoning and the importance of sorption hemoperfusion in its therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138600" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2918944" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11927904" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dialysis and hemoperfusion in poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837270" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22578059" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31621466" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hemoperfusion plus continuous veno-venous hemofiltration in the treatment of patients with multiple organ failure after wasp stings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34490152" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863114" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19531784" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862039" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30304428" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29204670" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246600" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Blood Purification and Mortality in Sepsis and Septic Shock: A Systematic Review and Meta-analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28343448" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hemoadsorption by CytoSorb in septic patients: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885411" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cytokine Reduction in the Setting of an ARDS-Associated Inflammatory Response with Multiple Organ Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31868089" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hemoadsorption treatment with CytoSorb®in patients with extracorporeal life support therapy: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448517" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084247" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059056" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32118713" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28970002" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immunoadsorption for collagen and rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28863794" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immunoadsorption in Autoimmune Diseases Affecting the Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26318215" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817118" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Immunoadsorption in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28919008" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Immunoadsorption in neurological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26425876" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264786" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Early Cytokine Removal in Critical COVID-19 Patients with Extracorporeal Therapies (HA-380 plus High Volume Hemofiltration) May Prevent Progression of Acute Respiratory Distress Syndrome: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34988092" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917741" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944029" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cytokine clearance with CytoSorb®during cardiac surgery: a pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/590850" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066188" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Early hemoperfusion for emergency treatment of carbamazepine poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27933591" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31527808" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
